ERBB2 and breast cancer: In addition, it was also reported that plasma levels of circulating glypican-4 in patients with ER+/HER2− metastatic BC predicted 24-month overall survival, indicating the potential of glypicans not only as cell-surface modulators but also as non-invasive prognostic biomarkers in BC [101].